BRAF and MEK inhibitors (BRAFi and MEKi) represent a breakthrough in the treatment of BRAF(V600E)-mutant cancers, greatly improving outcomes for cancer patients [13, 14]. This evidence concerns the gene MAP2K7 and cancer.